Elevated HbA1c levels in pre-Covid-19 infection increases the risk of mortality: A sistematic review and meta-analysis
- PMID: 34018307
- PMCID: PMC8209812
- DOI: 10.1002/dmrr.3476
Elevated HbA1c levels in pre-Covid-19 infection increases the risk of mortality: A sistematic review and meta-analysis
Abstract
Aims: Diabetes is emerging as a risk factor for coronavirus disease (COVID)-19 prognosis. However, contradictory findings have been reported regarding the impact of glycaemic control on COVID-19 outcome. The aim of this meta-analysis was to explore the impact of hospital pre-admission or at-admission values of HbA1c on COVID-19 mortality or worsening in patients with diabetes.
Materials and methods: We searched PubMed, Embase and Scopus up to 30th December 2020. Eligibility criteria for study selection were the following: (1)enrolling patients with any form of diabetes mellitus and hospitalized for COVID-19 and (2) reporting data regarding HbA1c values before infection or at hospital admission in relation to COVID-19 mortality or worsening. Descriptive statistics, HbA1c values, odds ratios (ORs) and hazard ratios were extracted from seven observational studies and generic inverse variance (random effects) of OR was used to estimate the effect of HbA1c on COVID-19 outcome.
Results: HbA1c was linearly associated with an increased COVID-19 mortality or worsening when considered as a continuous variable (OR 1.01 [1.01, 1.01]; p < 0.00001). Similarly, when analysing studies providing the number of events according to the degree of glycaemic control among various strata, a significantly increased risk was observed with poor glycaemic control (OR 1.15 [1.11, 1.19]; p < 0.00001), a result corroborated by sensitivity analysis.
Conclusions: Notwithstanding the large heterogeneity in study design and patients' characteristics in the few available studies, data suggest that patients with diabetes and poor glycaemic control before infection might have an increased risk of COVID-19 related mortality.
Keywords: COVID-19; COVID-19 prognosis; HbA1c; SARS-CoV-2; glycaemic control; mortality; outcomes; type 1 diabetes mellitus; type 2 diabetes mellitus.
© 2021 John Wiley & Sons Ltd.
Conflict of interest statement
All the authors declared that they have no conflict of interest.
Figures


Similar articles
-
Impact of Hyperglycemia on Cardiovascular Events and Clinical Outcomes in Patients Hospitalized With COVID-19 Pneumonia.Endocr Pract. 2022 Aug;28(8):780-786. doi: 10.1016/j.eprac.2022.05.011. Epub 2022 Jun 4. Endocr Pract. 2022. PMID: 35671878 Free PMC article.
-
Glycated haemoglobin levels among 3295 hospitalized COVID-19 patients, with and without diabetes, and risk of severe infection, admission to an intensive care unit and all-cause mortality.Diabetes Obes Metab. 2022 Mar;24(3):499-510. doi: 10.1111/dom.14604. Epub 2021 Dec 5. Diabetes Obes Metab. 2022. PMID: 34779086 Free PMC article.
-
Legacy effect of intensive glucose control on major adverse cardiovascular outcome: Systematic review and meta-analyses of trials according to different scenarios.Metabolism. 2020 Sep;110:154308. doi: 10.1016/j.metabol.2020.154308. Epub 2020 Jul 4. Metabolism. 2020. PMID: 32628943
-
Diabetes mellitus and HbA1c as predictors of mortality in hospitalized COVID-19 patients.Expert Rev Endocrinol Metab. 2025 May;20(3):221-232. doi: 10.1080/17446651.2025.2469627. Epub 2025 Feb 27. Expert Rev Endocrinol Metab. 2025. PMID: 40017013
-
The Impact of COVID-19 on Blood Glucose: A Systematic Review and Meta-Analysis.Front Endocrinol (Lausanne). 2020 Oct 5;11:574541. doi: 10.3389/fendo.2020.574541. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33123093 Free PMC article.
Cited by
-
Outpatient and inpatient anticoagulation therapy and the risk for hospital admission and death among COVID-19 patients.EClinicalMedicine. 2021 Nov;41:101139. doi: 10.1016/j.eclinm.2021.101139. Epub 2021 Sep 24. EClinicalMedicine. 2021. PMID: 34585129 Free PMC article.
-
Recent advances in nutritional metabolism studies on SARS-CoV-2 infection.Infect Med (Beijing). 2025 Jan 15;4(1):100162. doi: 10.1016/j.imj.2025.100162. eCollection 2025 Mar. Infect Med (Beijing). 2025. PMID: 39936106 Free PMC article. Review.
-
The Role of Glycemic Control in Inflammation Markers and Clinical Outcomes in Type 2 Diabetes Patients with Severe COVID-19.Biomedicines. 2025 Apr 6;13(4):886. doi: 10.3390/biomedicines13040886. Biomedicines. 2025. PMID: 40299484 Free PMC article.
-
COVID-19 Outcomes Stratified by Control Status of Hypertension and Diabetes: Preliminary Findings From PCORnet, U.S.AJPM Focus. 2022 Sep;1(1):100012. doi: 10.1016/j.focus.2022.100012. Epub 2022 Jul 10. AJPM Focus. 2022. PMID: 36942020 Free PMC article.
-
The Role of Diabetes and Hyperglycemia on COVID-19 Infection Course-A Narrative Review.Front Clin Diabetes Healthc. 2022 Mar 10;3:812134. doi: 10.3389/fcdhc.2022.812134. eCollection 2022. Front Clin Diabetes Healthc. 2022. PMID: 36992740 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous